Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients

Front Immunol. 2021 Jan 8:11:602395. doi: 10.3389/fimmu.2020.602395. eCollection 2020.

Abstract

The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.

Keywords: biomarker; coronavirus disease-2019 prognosis; cytokine serum profile; cytokine storm; interleukin-6; interleukin-8; respiratory syndrome coronavirus 2.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biomarkers / blood*
  • COVID-19 / blood*
  • COVID-19 / pathology*
  • COVID-19 / virology
  • Humans
  • Interleukin-6 / blood
  • Interleukin-8 / blood*
  • Prognosis
  • SARS-CoV-2 / pathogenicity
  • Severity of Illness Index

Substances

  • Biomarkers
  • Interleukin-6
  • Interleukin-8